Pre-treatment and in-vivo dosimetry of Helical Tomotherapy treatment plans using the Dosimetry Check system
Pre-treatment and in-vivo dosimetry of Helical Tomotherapy treatment plans using the Dosimetry Check system
复制标题
DOI：
10.1088/1748-0221/9/04/c04039
复制
发表时间：
2014-04-01
影响因子：
1.3
通讯作者：
Iori, M.
中科院分区：
文献类型：
--
作者：
Mezzenga, E.;Cagni, E.;Iori, M.
Dosimetry Check (DC) is the world's first commercially available software that provides patient-specific pre-treatment (PTD) and in-vivo transit (IVD) dose quality assurance of static and rotational intensity-modulated radiotherapy treatments. To investigate the feasibility of replacing pre-treatment verification with in vivo dosimetry for Helical Tomotherapy (HT), the commissioning and the application of the DC software was realised. Dose distributions were reconstructed from Mega Voltage Computed Tomography (MVCT) detectors, inside phantoms or patients for a total number of 6 treatment plans. Planned, reconstructed MVCT dose and measurements using ionisation chambers and a matrix detector inserted in cylindrical and octagonal phantoms, respectively, were compared at the isocenter and in two dimensions using the gamma(2D) and gamma(10)-index (3% / 3 mm). The dose reconstruction PTD and IVD methods of DC software provided, compared to detector measurements and for three Quality Assurance (QA) plans, similar point dose deviations and gamma(2D)-index passing rates: (0.4 +/- 0.1)% vs. (-1.4 +/- 1.6)%, and (96.8 +/- 0.9)% vs. (98.9 +/- 0.6)%, respectively. In terms of gamma(10)-index passing rate, PTD and IVD modalities reached mean values of (99.3 +/- 0.1)% and (97.2 +/- 1.9)%, respectively. Also for the remaining three clinical plans, similar results were reached for IVD with gamma(10)-index passing rate reaching mean values of (95.9 +/- 3.4)%. Therefore, either the PTD and the IVD verification modalities proved to be a very promising tool for the patient-specific QA of HT Plans.
